128 related articles for article (PubMed ID: 28772290)
1. Surveillance in Germline TP53 Mutation Carriers Utilizing Whole-Body Magnetic Resonance Imaging.
Ballinger ML; Ferris NJ; Moodie K; Mitchell G; Shanley S; James PA; Thomas DM
JAMA Oncol; 2017 Dec; 3(12):1735-1736. PubMed ID: 28772290
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.
Villani A; Shore A; Wasserman JD; Stephens D; Kim RH; Druker H; Gallinger B; Naumer A; Kohlmann W; Novokmet A; Tabori U; Tijerin M; Greer ML; Finlay JL; Schiffman JD; Malkin D
Lancet Oncol; 2016 Sep; 17(9):1295-305. PubMed ID: 27501770
[TBL] [Abstract][Full Text] [Related]
3. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.
Bojadzieva J; Amini B; Day SF; Jackson TL; Thomas PS; Willis BJ; Throckmorton WR; Daw NC; Bevers TB; Strong LC
Fam Cancer; 2018 Apr; 17(2):287-294. PubMed ID: 28988289
[TBL] [Abstract][Full Text] [Related]
4. Surveillance of Dutch Patients With Li-Fraumeni Syndrome: The LiFe-Guard Study.
Ruijs MWG; Loo CE; van Buchem CAJM; Bleiker EMA; Sonke GS
JAMA Oncol; 2017 Dec; 3(12):1733-1734. PubMed ID: 28772294
[TBL] [Abstract][Full Text] [Related]
5. Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic
Bancroft EK; Saya S; Brown E; Thomas S; Taylor N; Rothwell J; Pope J; Chamberlain A; Page E; Benafif S; Hanson H; Dias A; Mikropoulos C; Izatt L; Side L; Walker L; Donaldson A; Cook JA; Barwell J; Wiles V; Limb L; Eccles DM; Leach MO; Shanley S; Gilbert FJ; Gallagher D; Rajashanker B; Whitehouse RW; Koh DM; Sohaib SA; Evans DG; Eeles RA; Walker LG
J Med Genet; 2020 Apr; 57(4):226-236. PubMed ID: 31719169
[TBL] [Abstract][Full Text] [Related]
6. Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial.
Caron O; Frebourg T; Benusiglio PR; Foulon S; Brugières L
JAMA Oncol; 2017 Dec; 3(12):1736-1737. PubMed ID: 28772306
[TBL] [Abstract][Full Text] [Related]
7. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.
Villani A; Tabori U; Schiffman J; Shlien A; Beyene J; Druker H; Novokmet A; Finlay J; Malkin D
Lancet Oncol; 2011 Jun; 12(6):559-67. PubMed ID: 21601526
[TBL] [Abstract][Full Text] [Related]
8. Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.
Ballinger ML; Best A; Mai PL; Khincha PP; Loud JT; Peters JA; Achatz MI; Chojniak R; Balieiro da Costa A; Santiago KM; Garber J; O'Neill AF; Eeles RA; Evans DG; Bleiker E; Sonke GS; Ruijs M; Loo C; Schiffman J; Naumer A; Kohlmann W; Strong LC; Bojadzieva J; Malkin D; Rednam SP; Stoffel EM; Koeppe E; Weitzel JN; Slavin TP; Nehoray B; Robson M; Walsh M; Manelli L; Villani A; Thomas DM; Savage SA
JAMA Oncol; 2017 Dec; 3(12):1634-1639. PubMed ID: 28772291
[TBL] [Abstract][Full Text] [Related]
9. Increased sperm aneuploidy in two male carriers of germline TP53 mutations.
Paulasova P; Diblik J; Trkova M; Macek M; Sedlacek Z
Cancer Genet; 2011 May; 204(5):278-81. PubMed ID: 21665182
[TBL] [Abstract][Full Text] [Related]
10. Surveillance recommendations for patients with germline TP53 mutations.
Ballinger ML; Mitchell G; Thomas DM
Curr Opin Oncol; 2015 Jul; 27(4):332-7. PubMed ID: 26049273
[TBL] [Abstract][Full Text] [Related]
11. Transmission of a
Cotter JA; Szymanski L; Karimov C; Boghossian L; Margol A; Dhall G; Tamrazi B; Varaprasathan GI; Parham DM; Judkins AR; Biegel JA
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29581140
[TBL] [Abstract][Full Text] [Related]
12. Whole-body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study.
Omran M; Johansson H; Lundgren C; Silander G; Stenmark-Askmalm M; Loman N; Baan A; Adra J; Kuchinskaya E; Blomqvist L; Tham E; Bajalica-Lagercrantz S; Brandberg Y;
Cancer; 2023 Mar; 129(6):946-955. PubMed ID: 36601958
[TBL] [Abstract][Full Text] [Related]
13. Contribution of genotoxic anticancer treatments to the development of multiple primary tumours in the context of germline TP53 mutations.
Kasper E; Angot E; Colasse E; Nicol L; Sabourin JC; Adriouch S; Lacoume Y; Charbonnier C; Raad S; Frebourg T; Flaman JM; Bougeard G
Eur J Cancer; 2018 Sep; 101():254-262. PubMed ID: 30072235
[TBL] [Abstract][Full Text] [Related]
14. Germline TP53 mutations and Li-Fraumeni syndrome.
Varley JM
Hum Mutat; 2003 Mar; 21(3):313-20. PubMed ID: 12619118
[TBL] [Abstract][Full Text] [Related]
15. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel TP53 germline mutation in a large Italian Li-Fraumeni syndrome Family.
Capra V; Consales A; Nozza P; Monti P; Inga A; Fronza G
Pediatr Blood Cancer; 2009 Feb; 52(2):303-4. PubMed ID: 18937320
[No Abstract] [Full Text] [Related]
17. Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort.
Mai PL; Khincha PP; Loud JT; DeCastro RM; Bremer RC; Peters JA; Liu CY; Bluemke DA; Malayeri AA; Savage SA
JAMA Oncol; 2017 Dec; 3(12):1640-1645. PubMed ID: 28772286
[TBL] [Abstract][Full Text] [Related]
18. Identification and Management of
Pal T; Brzosowicz J; Valladares A; Wiesner GL; Laronga C
South Med J; 2017 Oct; 110(10):643-648. PubMed ID: 28973705
[TBL] [Abstract][Full Text] [Related]
19. Sex-specific effect of the TP53 PIN3 polymorphism on cancer risk in a cohort study of TP53 germline mutation carriers.
Fang S; Krahe R; Bachinski LL; Zhang B; Amos CI; Strong LC
Hum Genet; 2011 Dec; 130(6):789-94. PubMed ID: 21688173
[TBL] [Abstract][Full Text] [Related]
20. Parent decision-making around the genetic testing of children for germline TP53 mutations.
Alderfer MA; Zelley K; Lindell RB; Novokmet A; Mai PL; Garber JE; Nathan D; Scollon S; Chun NM; Patenaude AF; Ford JM; Plon SE; Schiffman JD; Diller LR; Savage SA; Malkin D; Ford CA; Nichols KE
Cancer; 2015 Jan; 121(2):286-93. PubMed ID: 25223899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
